Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
20.50
+0.39 (1.94%)
Jun 18, 2026, 3:04 PM CST
Market Cap9.79B +38.7%
Revenue (ttm)203.92M -30.4%
Net Income-83.86M
EPS-0.18
Shares Out 477.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume30,004,302
Open20.39
Previous Close20.11
Day's Range19.71 - 21.68
52-Week Range19.71 - 66.66
Beta0.43
AnalystsStrong Buy
Price Target55.24 (+169.46%)
Earnings DateAug 27, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 491
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2025, SHE:300204's revenue was 220.23 million, a decrease of -32.20% compared to the previous year's 324.82 million. Losses were -77.76 million, -46.31% less than in 2024.

Financial Statements